Andrea Wang‐Gillam

Author

Andrea Wang‐Gillam

Washington University in St. Louis ORCID

Also Known As

A. Wang-Gillam, Andrea Wang-Gillam, Andrea Wang-Gillam (468731), Andrea Wang‐Gillam, Andrea wang-gillam, Cox, Adrienne D, D Linehan, Lee M. Graves, Long, Brian, Wang-Gillam, Andrea

430

Publications

15.1K

Citations

H-Index

Concepts

All Affiliations

Washington University in St. Louis Fred Hutch Cancer Center The Barbara Ann Karmanos Cancer Institute Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center

About

Andrea Wang‐Gillam is an author at Washington University in St. Louis specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	60	6.5K
2	Health Sciences	11	12	376
3	Cell Biology	9	9	2.5K
4	Engineering	1	1	21
5	Biostatistics	1	1	14

Andrea Wang‐Gillam

111

Publications

12.7K

Citations

H-Index

Page 1

	Year	Citations
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models Yu Zhu, Brett L. Knolhoff, Melissa A. Meyer, Cancer Research	2014	1.3K
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky, The Lancet NanomedicineOncologyPancreatic CancerMedicineFolinic Acid	2015	1.2K
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy Hong Jiang, Samarth Hegde, Brett L. Knolhoff, Nature Medicine OncologyPancreatic CancerMedicineReceptor Tyrosine KinaseImmunology	2016	991
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses Jonathan B. Mitchem, Donal J. Brennan, Brett L. Knolhoff, Cancer Research ImmunologyBiological MicroenvironmentsImmunoeditingImmunologic MechanismImmunotherapy	2012	929
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial Timothy M. Nywening, Andrea Wang‐Gillam, Dominic E. Sanford, The Lancet Oncology Pancreatic CancerTumour-associated MacrophagesMedicineImmunologyCcr2 Inhibition	2016	746
Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis Dominic E. Sanford, Brian A. Belt, Roheena Z. Panni, Clinical Cancer Research	2013	597
Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i>–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer Dung T. Le, Andrea Wang‐Gillam, Vincent J. Picozzi, Journal of Clinical Oncology	2015	588
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma Sunil R. Hingorani, Lei Zheng, Andrea J. Bullock, Journal of Clinical Oncology NanotherapeuticsPathologyPhase Ii StudyTumor BiologyOncology	2017	467
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú, Cancer Discovery	2017	401
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke, European Journal of Cancer	2019	299

Page 1